[go: up one dir, main page]

WO2003048383A3 - Effectors of innate immunity - Google Patents

Effectors of innate immunity Download PDF

Info

Publication number
WO2003048383A3
WO2003048383A3 PCT/CA2002/001830 CA0201830W WO03048383A3 WO 2003048383 A3 WO2003048383 A3 WO 2003048383A3 CA 0201830 W CA0201830 W CA 0201830W WO 03048383 A3 WO03048383 A3 WO 03048383A3
Authority
WO
WIPO (PCT)
Prior art keywords
pattern
peptide
inflammatory
innate immunity
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2002/001830
Other languages
French (fr)
Other versions
WO2003048383A2 (en
Inventor
Robert E W Hancock
B Brett Finlay
Monisha Gough Scott
Dawn Bowdish
Carrie Melissa Rosenberger
Jon-Paul Steven Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003549560A priority Critical patent/JP2005536985A/en
Priority to KR10-2004-7008519A priority patent/KR20040077669A/en
Priority to EP20020804139 priority patent/EP1470249A2/en
Priority to HK05107785.9A priority patent/HK1075677B/en
Priority to IL16230002A priority patent/IL162300A0/en
Priority to CA002468907A priority patent/CA2468907A1/en
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to AU2002365675A priority patent/AU2002365675B2/en
Priority to NZ533721A priority patent/NZ533721A/en
Publication of WO2003048383A2 publication Critical patent/WO2003048383A2/en
Anticipated expiration legal-status Critical
Publication of WO2003048383A3 publication Critical patent/WO2003048383A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

A method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a peptide is described. A method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response. The method includes contacting cells with LPS, LTA, CpG DNA and/or intact microbes or microbial components in the presence or absence of a peptide; detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide, wherein the pattern in the presence of the peptide represents inhibition of an inflammatory or septic response. Also included are compounds and agents identified by the methods of the invention. In another aspect, the invention provides methods and compounds for enhancing innate immunity in a subject.
PCT/CA2002/001830 2001-12-03 2002-12-02 Effectors of innate immunity Ceased WO2003048383A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR10-2004-7008519A KR20040077669A (en) 2001-12-03 2002-12-02 Effectors of innate immunity
EP20020804139 EP1470249A2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity
HK05107785.9A HK1075677B (en) 2001-12-03 2002-12-02 Effectors of innate immunity
IL16230002A IL162300A0 (en) 2001-12-03 2002-12-02 Effectors of innate immunity
CA002468907A CA2468907A1 (en) 2001-12-03 2002-12-02 Effectors of innate immunity
JP2003549560A JP2005536985A (en) 2001-12-03 2002-12-02 Innate immune effector
AU2002365675A AU2002365675B2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity
NZ533721A NZ533721A (en) 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
US60/336,632 2001-12-03

Publications (2)

Publication Number Publication Date
WO2003048383A2 WO2003048383A2 (en) 2003-06-12
WO2003048383A3 true WO2003048383A3 (en) 2004-08-05

Family

ID=23316965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001830 Ceased WO2003048383A2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Country Status (11)

Country Link
EP (1) EP1470249A2 (en)
JP (1) JP2005536985A (en)
KR (1) KR20040077669A (en)
CN (2) CN101215601A (en)
AU (1) AU2002365675B2 (en)
CA (1) CA2468907A1 (en)
IL (1) IL162300A0 (en)
NZ (2) NZ533721A (en)
SG (1) SG159382A1 (en)
WO (1) WO2003048383A2 (en)
ZA (1) ZA200404919B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
US20060014136A1 (en) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals, Inc. Method of screening for protection from microbial infection
WO2006137444A1 (en) * 2005-06-22 2006-12-28 Seikagaku Corporation Method of eliminating reactivity from lipoarabinomannan and application of the same
GB0517090D0 (en) 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
US20080118525A1 (en) * 2006-10-04 2008-05-22 Oreola Donini Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
PL2236608T3 (en) * 2005-10-04 2017-06-30 Soligenix, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
ES2497441T3 (en) 2006-08-21 2014-09-22 The University Of British Columbia Small cationic immunomodulatory peptides
WO2009057695A1 (en) * 2007-10-30 2009-05-07 Olympus Corporation Method for detection of adenoma or cancer by genetic analysis
WO2010026489A1 (en) * 2008-09-05 2010-03-11 The University Of British Columbia Innate immunity modulators
WO2010042534A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides and methods of use
AR091069A1 (en) 2012-05-18 2014-12-30 Amgen Inc PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
WO2023063994A1 (en) * 2021-10-13 2023-04-20 Phenomune, LLC Testing methods for determination of t2r phenotype and applications thereof
KR20250044488A (en) * 2023-09-21 2025-04-01 성균관대학교산학협력단 Composition for treating sepsis that controls odorant receptor Olfr164

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
WO2000012528A1 (en) * 1998-08-28 2000-03-09 University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US6040435A (en) * 1995-06-02 2000-03-21 University Of British Columbia Antimicrobial cationic peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040435A (en) * 1995-06-02 2000-03-21 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
WO2000012528A1 (en) * 1998-08-28 2000-03-09 University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] NCBI; 12 June 1993 (1993-06-12), MISHIMA K ET AL.: "ARD1, a 64-kDa guanine nucleotide-binding protein with a carboxyl-terminal ADP-ribosylation factor domain", XP002265873, accession no. WWW.NCBI.NLM Database accession no. L04510 *
DATABASE GENBANK [online] NCBI; 4 April 1996 (1996-04-04), LUTFALLA G ET AL.: "Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster", XP002265872, accession no. WWW.NCBI.NLM Database accession no. L42243 *
DORANZ B J ET AL: "A SMALL-MOLECULE INHIBITOR DIRECTED AGAINST THE CHEMOKINE RECEPTOR CXCR4 PREVENTS ITS USE AS AN HIV-1 CORECEPTOR", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1395 - 1400, XP000669413, ISSN: 0022-1007 *
HANCOCK R E ET AL: "The role of antimicrobial peptides in animal defenses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 1 AUG 2000, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 8856 - 8861, XP002265556, ISSN: 0027-8424 *
HANCOCK R E W ET AL: "Cationic peptides: a new source of antibiotics", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 16, no. 2, 1 February 1998 (1998-02-01), pages 82 - 88, XP004107047, ISSN: 0167-7799 *
HANCOCK R E: "Cationic peptides: effectors in innate immunity and novel antimicrobials.", THE LANCET INFECTIOUS DISEASES. OCT 2001, vol. 1, no. 3, October 2001 (2001-10-01), pages 156 - 164, XP002277968, ISSN: 1473-3099 *
MCQUIBBAN G A ET AL: "Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 23 NOV 2001, vol. 276, no. 47, 23 November 2001 (2001-11-23), pages 43503 - 43508, XP002277969, ISSN: 0021-9258 *
SARENEVA T ET AL: "IFN-ALPHA AND IL-12 INDUCE IL-18 RECEPTOR GENE EXPRESSION IN HUMAN NK AND T CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 165, no. 4, 15 August 2000 (2000-08-15), pages 1933 - 1938, XP001156177, ISSN: 0022-1767 *
SCOTT M G ET AL: "CATIONIC ANTIMICROBIAL PEPTIDES AND THEIR MULTIFUNCTIONAL ROLE IN THE IMMUNE SYSTEM", CRITICAL REVIEWS IN IMMUNOLOGY, CRC PRESS, INC, XX, vol. 20, no. 5, 2000, pages 407 - 431, XP009021954, ISSN: 1040-8401 *
SCOTT MG. ET AL.: "An alpha-Helical Cationic Antimicrobial Peptide Selectively Modulates Macrophage Responses to Lipopolysaccharide and Directly Alters Macrophage Gene Expression", THE JOURNAL OF IMMUNOLOGY, vol. 165, 2000, pages 3358 - 3365, XP002263247 *
SCOTT MG. ET AL.: "Biological Properties of Structurally Related alpha-Helical Cationic Antimicrobial Peptides", INFECTION AND IMMUNITY, vol. 67, no. 4, April 1999 (1999-04-01), pages 2005 - 2009, XP002263248 *
WETERING VAN S ET AL: "DEFENSINS: KEY PLAYERS OR BYSTANDERS IN INFECTION, INURY, AND REPAIR IN THE LUNG?", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 104, no. 6, 1999, pages 1131 - 1138, XP009021951, ISSN: 0091-6749 *
WU HUA ET AL: "Regulation of cathelicidin gene expression: Induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar Typhimurium infection", INFECTION AND IMMUNITY, vol. 68, no. 10, October 2000 (2000-10-01), &, pages 5552 - 5558, XP002277967, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
NZ563261A (en) 2008-08-29
IL162300A0 (en) 2005-11-20
NZ533721A (en) 2007-12-21
JP2005536985A (en) 2005-12-08
CN1615368A (en) 2005-05-11
AU2002365675B2 (en) 2007-04-05
EP1470249A2 (en) 2004-10-27
ZA200404919B (en) 2006-05-31
SG159382A1 (en) 2010-03-30
CA2468907A1 (en) 2003-06-12
AU2002365675A1 (en) 2003-06-17
CN101215601A (en) 2008-07-09
CN100357324C (en) 2007-12-26
HK1075677A1 (en) 2005-12-23
KR20040077669A (en) 2004-09-06
WO2003048383A2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
WO2003048383A3 (en) Effectors of innate immunity
WO2001048237A3 (en) Method for quickly detecting microbial dna/rna, kit therefor and the use of said method
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
AU6152301A (en) Detection of nucleic acid hybridization by fluorescence polarization
DE60125243D1 (en) POLYNUCLEOTIDE SEQUENCE ASSAY
WO2003036265A8 (en) Assay systems with adjustable fluid communication
WO1999007887A3 (en) A method of removing nucleic acid contamination in amplification reactions
AU2001274560A1 (en) Substrate activation kit and method of detecting dna or the like by using the same
AU1728001A (en) Oligonucleotides and assemblies thereof useful in the detection of the presence or absence of target nucleic acid sequences in a sample
WO2005017202A3 (en) Method and kit for identifying antibiotic-resistant microorganisms
AU8398801A (en) Two coloured fluorimetric protease assay
WO2001066797A3 (en) Multiplex hybridization system for identification of pathogenic mycobacterium and method of use
DE60332378D1 (en) POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE
DE60130970D1 (en) REAGENT SET FOR DETECTING MICROORGANISMS, APPARATUS FOR QUANTIFYING MICROORGANISMS AND METHOD FOR QUANTIFYING MICROORGANISMS
WO2001029262A3 (en) Genotyping reagents, kits and methods of use thereof
WO2003048310A3 (en) Thermus oshimai nucleic acid polymerases
WO2004009839A3 (en) Oligonucleotides for detecting micro-organisms
WO2004009843A3 (en) Detection of microorganisms
WO2001061038A3 (en) Method for detecting a biological entity in a sample
WO1999005159A3 (en) Staphylococcus specific nucleic acid molecule, test kit and utilization of the nucleic acid molecule and test kit
WO2001068900A3 (en) Method for specifically detecting microorganisms by polymerase chain reaction
ATE447582T1 (en) MOLECULAR IDENTIFICATION OF BACTERIA OF THE GENUS STREPTOCOCCUS AND RELATED GENUS
BR9910646A (en) Detection of antibiotic resistance in microorganisms
ATE321889T1 (en) METHOD FOR DETECTING MICROORGANISMS
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2468907

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003549560

Country of ref document: JP

Ref document number: 162300

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020047008519

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1756/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/04919

Country of ref document: ZA

Ref document number: 2002365675

Country of ref document: AU

Ref document number: 200404919

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 533721

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200400626

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2002804139

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028273273

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002804139

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002365675

Country of ref document: AU